Chen Sun

Dr. Chen Sun


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SFSofia España Fernandez
Sofia España Fernandez
CSChen Sun
Chen Sun
CSCarme Solé-Blanch
Carme Solé-Blanch
Aram BoadaAram Boada
Aram Boada
ACAnna Martinez Cardus
Anna Martinez Cardus
JMJose Luis Manzano
Jose Luis Manzano
Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum previously unknown to clinicians, until now. A common situation in daily practice is that a patient experiences toxicity due to this type of drug and we need to resume or rechallenge treatment after resolving the adverse event. Methods: A PubMed literature review was carried out. Results: The published data regarding the resumption or rechallenge of ICI treatment in melanoma patients is scarce and heterogeneous. Depending on the study reviewed, the recurrence incidence of grade 3–4 immune-related adverse events (irAEs) ranged from 18% to 82%. Conclusion: It is possible to resume or rechallenge, but each patient should be evaluated by a multidisciplinary team for close monitoring and assessment of the risk/benefit ratio before initiating treatment.